Publications by authors named "A S Zhilenkova"

Lung cancer is currently the second leading cause of cancer death worldwide. In recent years, checkpoint inhibitor immunotherapy (ICI) has emerged as a new treatment. A better understanding of the tumor microenvironment (TMJ) or the immune system surrounding the tumor is needed.

View Article and Find Full Text PDF

The death rate from cancer is declining as a result of earlier identification and more advanced treatments. Nevertheless, a number of unfavourable adverse effects, including prolonged, long-lasting inflammation and reduced immune function, usually coexist with anti-cancer therapies and lead to a general decline in quality of life. Improvements in standardized comprehensive therapy and early identification of a variety of aggressive tumors remain the main objectives of cancer research.

View Article and Find Full Text PDF
Article Synopsis
  • Research indicates that growth factors play a significant role in lung cancer angiogenesis, which helps tumors grow and spread by affecting the immune response.
  • New treatment strategies focus on developing anti-angiogenic compounds that block the activity of these growth factors, particularly EGF and VEGF, to hinder lung cancer progression.
  • While the initial results of these therapies are promising, there is a heightened risk of toxicity, necessitating personalized follow-up care for patients undergoing treatment.
View Article and Find Full Text PDF

The article provides an overview of current information on the pathogenesis of COVID-19 and organ-specific lesions developing in this disease. The data on inflammation and its biochemical markers, on the features of coagulopathy, endothelial damage and microthrombosis are presented in detail. Particular attention is paid to the role of receptors for angiotensin converting enzyme type 2 and transmembrane serine protease type 2 in the development of organ-specific lesions in COVID-19.

View Article and Find Full Text PDF

Background: HIV-infection is known to aggravate the course of many infectious diseases, including COVID-19. International guidance recommends vaccination of HIV+ individuals against SARS-CoV-2. There is a paucity of data on epidemiological efficacy assessment of COVID-19 vaccines among HIV+.

View Article and Find Full Text PDF